After birth, parathyroid hormone (PTH), produced in the parathyroid gland, regulates extracellular calcium, phosphate, and bone metabolism by replacing PTH-related protein (PTHrP), which has a similar function specifically in the fetal period. In contrast, humoral hypercalcemia of malignancy develops mostly by the robust reactivation of PTHrP production in adults when primary tumors acquire advanced aggressive characteristics \[[@B1], [@B2]\].

Paraneoplastic syndromes associated with malignant tumors, such as non--small lung cancers, are accompanied frequently by the ectopic production of peptide hormones \[[@B3]\]. However, the ectopic production of PTH, but not PTHrP, in malignancy is very rare, with merely 23 documented cases ([Table 1](#T1){ref-type="table"}). Accordingly, the etiology of ectopic PTH production remains elusive, except for a large gene rearrangement involving the PTH gene locus \[[@B4]\] or CpG hypomethylation of the PTH promoter \[[@B5]\]. We speculated that the parathyroid cell-specific expression of the PTH gene must be controlled extremely stringently and that escape from such restriction might be too difficult to permit PTH gene expression in nonparathyroid cells.

###### 

**Ectopic PTH-Producing Tumors and Molecular Analyses**

  Patient Histopathologic Type                Detection of PTH RNA (Left) or Protein (Right)   Structural Alteration in PTH Gene   Reference             
  ------------------------------------------- ------------------------------------------------ ----------------------------------- --------------------- ---------------
  Small cell lung cancer                      \+                                               \+                                                        \[[@B6]\]
  Clear cell ovarian adenoma                  \+                                               \+                                  Rearrangement         \[[@B4]\]
  Endometrial cancer                                                                           \+                                                        \[[@B7]\]
  Neuroectodermal malignancy                  \+                                                                                                         \[[@B8]\]
  Thymoma                                     \+                                               \+                                                        \[[@B9]\]
  Squamous cell lung cancer                                                                    \+                                                        \[[@B10]\]
  Papillary thyroid cancer                                                                     \+                                                        \[[@B11]\]
  Hepatocellular cancer                                                                                                                                  \[[@B12]\]
  Squamous cell lung cancer                                                                    \+                                                        \[[@B13]\]
  Small cell lung cancer                      \+                                               \+                                                        \[[@B14]\]
  Ovarian neuroendocrine cancer                                                                \+                                                        \[[@B15]\]
  Small cell cancer of the ovary                                                               \+                                                        \[[@B16]\]
  Nasopharyngeal rhabdomyosarcoma             \+                                                                                                         \[[@B17]\]
  Pancreatic neuroendocrine cancer                                                                                                                       \[[@B18]\]
  Cervical paraganglioma                                                                       \+                                                        \[[@B19]\]
  Hepatocellular cancer                                                                        \+                                                        \[[@B20]\]
  Pancreatic neuroendocrine cancer            \+                                               \+                                  CpG hypomethylation   \[[@B5]\]
  Papillary thyroid cancer                                                                     \+                                                        \[[@B21]\]
  Medullary thyroid cancer                    \+                                                                                                         \[[@B22]\]
  Thyrothymic ligament neuroendocrine tumor                                                    \+                                                        \[[@B23]\]
  Adrenal pheochromocytoma                                                                     \+                                                        \[[@B24]\]
  Hepatocellular cancer                                                                                                                                  \[[@B25]\]
  Gastric carcinoma                                                                            \+                                                        \[[@B26]\]
  Retroperitoneal MFH                         \+                                               \+                                  No mutations          Present study

We report a case of hypercalcemia caused by ectopic PTH production in retroperitoneal malignant fibrous histiocytoma (MFH). We performed whole exome sequencing and used microarray profiling to identify molecular regulators that have the capability to induce PTH expression.

First, we examined the involvement of the deranged vitamin D axis. Inactivation of the active vitamin D3--vitamin D receptor (VDR) system is closely related to the tumorigenesis of various cancer cells \[[@B27][@B28][@B29][@B30][@B31][@B32][@B33][@B34]--[@B35]\]. Indeed, cytochrome P450 family 24 subfamily A member 1 (CYP24A1), an inactivating enzyme of active 1,25-dihydroxyvitamin D3, is considered a potent oncogene \[[@B33], [@B35]\].

We also explored the expression of hypermethylated in cancer 1 (HIC1), a tumor suppressor and potent CYP24A1 inducer \[[@B36][@B37]--[@B38]\]. We then explored the possible involvement of the expression of another potent brake candidate for PTH expression, namely, the calcium-sensing receptor (CaSR), in this process. Lethal hypercalcemia has been induced by the systemic loss or mutation of the CaSR gene in mice and humans \[[@B39][@B40]--[@B41]\]. If any trigger serendipitously produces a tiny amount of PTH in certain nonparathyroid cells, its expression would then be increased by the ablation of CaSR and its intracellular signaling system in these cells. In addition, long noncoding RNAs (lncRNAs) are expressed in a markedly tissue-specific manner and are highly regulated during development and in response to physiological signals \[[@B42][@B43]--[@B44]\]. Thus, to identify other possible players in the process of tumorigenesis, we explored lncRNAs in the region surrounding the PTH gene in parathyroid adenoma (PA), PTH-producing MFH (MFH+P) samples, and other cultured cancer cells.

1. Materials and Methods {#s1}
========================

A. Samples, Cells, and Clinical Data {#s2}
------------------------------------

All samples were obtained after informed consent in accordance with protocols approved by the ethics committees at Teikyo University School of Medicine (approval no. 12-040), National Defense Medical College (approval no. 125), and the University of Tokyo (approval no. 2011--16). In addition to the patient's MFH, we analyzed PAs from two other unrelated patients from Teikyo University School of Medicine Hospital, and samples from either one or both were used in the corresponding experiments. All the patients' laboratory data were obtained from the Department of General Practice (K.U., Y. T.). The non--PTH-producing breast cancer cell lines MCF-7, MDA-MB-231, and T47D were purchased from American Type Culture Collection (Manassas, VA). HepG2 (hepatoma), LNCaP (prostate cancer), M059J (glioma), and H295R (adrenocortical cancer) cells were also from American Type Culture Collection. HaCaT (keratinocyte) cells were a gift from Dr. N. E. Fusenig at the Division of Differentiation and Carcinogenesis, German Cancer Research Center (Heidelberg, Germany). MT2 (T cell lymphoma), SKBR (breast cancer), and MDA-MB453 (breast cancer) cells were gifts from Dr. Shunji Takahashi at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. Rv22 (prostate cancer) cells were kindly provided by Dr. Shigeo Horie at Juntendo University Hospital.

B. PTH Histochemistry {#s3}
---------------------

For PTH protein staining, the resected MFH tumor was minced, submerged in Dulbecco's modified Eagle medium (DMEM), and incubated for 2 hours. The medium was assayed using a whole PTH assay kit (DS Pharma Biomedical, Osaka, Japan). For immunohistochemistry, formalin-fixed, paraffin-embedded sections were stained with mouse monoclonal anti-human PTH (1-34) anti-serum (AbD Serotec, Oxford, UK) using a VECTASTAIN Elite ABC kit (Vector Laboratories, Burlingame, CA). The primary anti-PTH antibody was used at concentrations of 1:1000, 1:250, 1:100, and 1:50, and the secondary antibodies were used at a concentration of 1:500. The MFH tumor was cultured in DMEM for 2 hours, followed by the measurement of whole PTH levels. A mock incubation medium served as the control.

C. Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction Analysis {#s4}
----------------------------------------------------------------------------------

Oligonucleotide primers are listed in Supplemental Table 1. Total RNA isolated using RNAiso Plus (TaKaRa Biotechnology, Shiga, Japan) was reverse transcribed by priming with random hexamers and an oligo(dT) primer (PrimeScript RT reagent kit; TaKaRa Biotechnology, Shiga, Japan) or an oligo(dT) primer alone. Unless stated otherwise, all complementary DNAs (cDNAs) were obtained using a PrimeScript RT reagent kit with genomic DNA Eraser (TaKaRa Biotechnology). In the MFH, because the sample volume was limited, the absence of genomic DNA in the sample was verified using reverse transcription-free procedures or several unrelated intergenic and nonexonic primers as negative controls.

Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) analysis was performed using a Thermal Cycler Dice TM TP860 and SYBR Premix EXTaqII (TaKaRa Biotechnology). Samples were run in triplicate, unless stated otherwise. IBM SPSS Statistics, version 21, software (IBM Corp., Armonk, NY) was used for statistical analysis. We used one or two PAs from the patients, the MFH+P sample, and various cultured cancer cells. In some experiments, one to four non--PTH-producing MFH samples other than the MFH+P were included. For CaSR, VDR, and CYP24A1 amplification in the qRT-PCR assays, two sets of each primer (denoted −a and −b) were used.

D. DNA Sequencing {#s5}
-----------------

We synthesized PTH cDNA from RNA that was reverse transcribed with an oligo(dT) primer (TaKaRa Biotechnology), amplified a 697-bp cDNA product (coding capacity, between the 61st and 408th nucleotides) and cloned it into the pBluescript II SK(+) vector (Agilent Technologies, Santa Clara, CA). Two independent clones were sequenced on both strands. Genomic DNA was extracted from the MFH+P sample and the patients' leukocytes using the Wizard SV Genomic DNA Purification System (Promega, Madison, WI) and a QIAamp DNA Mini kit (QIAGEN, Hilden, Germany), respectively. To sequence the promoter region, nine overlapping DNA fragments (approximately 800 bp in size), covering a region from 5.7 kbp upstream to 360 bp downstream of the transcription start site, were amplified using PCR. This region was cloned into the pBluescript II SK(+) vector, and two to four independent clones were sequenced on both strands. PTH promoter genomic DNA from the tumor was converted with bisulfite using a MethylEasy Xceed Rapid DNA Bisulphite Modification Kit (Human Genetic Signatures, Sydney, Australia). A 232-bp fragment corresponding to −1312 to −1081 bp from the transcription start site, which contains two CpG sites, was amplified by PCR and cloned into the pGEM-T Easy vector (Promega, Madison, WI). Nine clones from the tumor and three clones from the PA were sequenced on both strands.

E. Gene Expression Profiling {#s6}
----------------------------

The patient's MFH+P sample with his white blood cells (WBCs) as controls were used, and total RNA was extracted and labeled with biotin. Ten micrograms of biotin-labeled commentary RNA was hybridized to gene-specific probes on the Human Genome U133 Plus 2.0 Array according to the GeneChip 3′IVT Express Kit User Manual (Affymetrix, Santa Clara, CA). The signal level of each transcript was calculated using Affymetrix GeneChip Command Console software (Affymetrix, Santa Clara, CA). Microarray results were compared with those of four non--PTH-producing cases (GSM149191, GSM149193, GSM149194, and GSM149200) of MFH registered with Gene Expression Omnibus as GSE6481 \[[@B45]\]. Because the scaling of the microarray data matched that of GSE6481, the data were normalized such that the trim average of the signal level became 100 (MAS 5.0 algorithm). Probe set identifications that were common in the Affymetrix Human Genome U133A Array of GSE6481 were extracted. For an obtained transcript, an expression ratio based on Log2(non--PTH-producing/PTH-producing) was calculated. The probe sets showing an expression ratio that increased by more than twofold or decreased by more than one-half in the MFH+P compared with any of the other four MFHs were extracted, forming two groups of upregulated and downregulated gene sets, respectively. For each single gene in each group, based on the National Center for Biotechnology Information Entrez Gene identification, gene ontology terms were assigned. The frequency of gene ontology terms in a group was calculated, and their statistical significance (*P* value) was examined (TaKaRa Biotechnology).

F. Immunofluorescence {#s7}
---------------------

Specimens were collected at surgery from the patients. The patients' tissue samples were embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek Japan, Tokyo, Japan) in liquid nitrogen. Tissue sections (6 to 7 µm) were cut using a cryomicrotome (CM3050S; Leica Microsystems, Nussloch, Germany) at −21°C. For fixation, the samples were incubated in 4% paraformaldehyde in phosphate-buffered saline (PBS) for 20 minutes at room temperature.

Permeabilization was performed with 0.25% Triton X-100 in PBS for 20 minutes at room temperature. Nonspecific binding was blocked by incubation in 3% bovine serum albumin and 0.1% Triton X-100 in PBS for 1 hour at room temperature. The antibodies were diluted in this blocking solution at the indicated concentrations and incubated for 2 hours at room temperature. Secondary antibodies were also diluted in the blocking solution and incubated for 1 hour at room temperature. Nuclei were stained with 2 μg/mL 496-diamidine-29-phenylindole dihydrochloride (Roche, Mannheim, Germany) in PBS for 15 minutes at room temperature. Images were acquired using a laser-scanning confocal image system (A1R-A1 Confocal Microscope System; Nikon, Tokyo, Japan). The primary anti-CYP24A1, anti-VDR, and anti-CaSR antibodies were used at concentrations of 1:50, 1:100, and 1:50, respectively, and secondary antibodies were used at a concentration of 1:500 \[[@B46]\]. The following antibodies were used in the immunofluorescence analysis: anti-human CYP24A1 rabbit polyclonal antibody (H-87; catalog no. sc-66851; Santa Cruz Biotechnology, Santa Cruz, CA); antihuman VDR (D2K6W) rabbit monoclonal antibody (catalog no. 12550; Cell Signaling Technology, Danvers, MA); and anti-human CaSR mouse monoclonal antibody (5C10, ADD; ab19347; Abcam, Cambridge, UK). The secondary antibodies were Alexa Fluor 647 goat anti-mouse/rabbit IgG (H+L) (A-21236/A-21245; Molecular Probes, Eugene, OR).

G. RT-PCR for Longer cDNA Fragments and Identification of lncRNAs {#s8}
-----------------------------------------------------------------

RNAs whose quality was strictly verified as described were analyzed to identify lncRNAs that were expressed exclusively in the MFH+P tumor. Various RNAs in the cultured cells, MFH+P, and PAs, which were transcribed from approximately 50-kb regions of the PTH gene, including its 3′-flanking region, were used. For the initial shotgun real-time RT-PCR analyses, parts of candidate lncRNAs were amplified using \>40 sets of randomly chosen, but PCR-suitable, primers. Subsequently, amplification of candidate lncRNAs was performed using each primer pair covering 1 to 5 kb, with a denaturation step at 94°C for 2 minutes, followed by 37 cycles of denaturation at 95°C for 10 seconds, primer annealing at 65°C for 30 seconds, and primer extension at 68°C for 3.5 minutes in a reaction volume of 50 μL using the KOD FX Neo polymerase system (Toyobo, Osaka, Japan). The reaction samples were stored at 4°C. Detection was performed with 0.9% agarose gel electrophoresis. The results of qRT-PCR for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or *β*-actin were used as a control. To examine the lncRNAs, either oligo(dT)- or random primer-derived RNAs from the PA, MFH+P, and various cultured cells were obtained. Finally, publicly open databases for whole genome RNA sequencing were reviewed to examine whether the lncRNAs found were registered in any of the databases. The presence of RNA in all samples, even when no lncRNA was amplified, was confirmed by the presence of GAPDH messenger RNA (mRNA). Samples obtained during the RNA extraction step still containing both genomic DNA and RNA were used to prove the validity of the primers

H. Exome Capture, Library Construction, and Sequencing {#s9}
------------------------------------------------------

One microgram of DNA per sample was sheared using a Covaris SS Ultrasonicator (Covaris Inc., Woburn, MA). We used a Sciclone NGS workstation (Caliper Life Sciences, Hopkinton, MA) for automated library construction. Exome capture was performed using an Agilent SureSelect Human All Exon Kit, version 4 (Agilent Technologies). Each sample was sequenced on an Illumina HiSEquation 2000 instrument using a read length of 2 × 100 bp. Image analysis and base calling were performed using the Illumina pipeline with default settings.

I. Exome Sequence Processing {#s10}
----------------------------

Burrows-Wheeler Aligner and NovoAlign software were used to align the sequence reads to the human reference genome (GRCh37/hg19). After removal of PCR duplicates, we used SRMA33 to improve variant discovery through local realignments of short-read next-generation sequencing data. Tumor cellularity was estimated from an allelic imbalance in the matched tumor and normal samples (patient's WBCs) with a program examining the allelic fractions of heterozygous single nucleotide polymorphisms in regions with a loss of heterozygosity using an algorithm similar to that described previously \[[@B47]\]. Consequently, somatic mutant allele frequencies ≥15%, adjusted by the estimated tumor content ratios, were retained. Artifacts originating from errors in the sequence and mapping were also filtered out by checking the single nucleotide variation (SNV) positions and base quality scores for the supporting reads. Fisher's exact test was then used, and SNV candidates with *P* \> 0.2 were removed. To eliminate germline variations in the present study, we performed comparative analyses using paired tumor and WBC samples from the same patient and extracted the somatic events detected only in tumor tissues. SNVs were annotated using ANNOVAR, version 36.

2. Results {#s11}
==========

A. Case Report {#s12}
--------------

A 69-year-old man with dehydration was admitted to the National Defense Medical College Hospital for the investigation of severe hypercalcemia. Laboratory data on admission ([Table 2](#T2){ref-type="table"}) revealed that the corrected serum calcium level was 18.2 mg/dL, serum intact PTH (iPTH) was 532 pg/mL, PTHrP was \<1 pmol/L, and serum 1,25-dihydroxyvitamin D3 was 6.8 pg/mL.

###### 

**Laboratory Findings on Admission**

  Variable                         Result   Reference Range
  -------------------------------- -------- -----------------
  Albumin, g/dL                    3.4      3.9--4.9
  BUN, mg/dL                       56       8.0--20.0
  Creatinine, mg/dL                2.43     0.5--1.0
  Sodium, mEq/L                    126      135--149
  Potassium, mEq/L                 3.8      3.5--4.9
  Chloride, mEq/L                  94       96--108
  Calcium, mg/dL                   17.6     8.4--10.4
  Phosphate, mg/dL                 4.6      2.5--4.5
  Magnesium, mg/dL                 3.7      1.9--2.5
  Intact PTH, pg/mL                532      10--65
  PTHrP, pmol/L                    \<1.0    \<1.0
  1,25-Dihydroxyvitamin D3, pg/m   6.8      20--60

Abbreviation: BUN, blood urea nitrogen.

Hypercalcemia with elevated serum iPTH suggested primary hyperparathyroidism; however, we failed to detect any evidence for hyperparathyroidism on standard image analyses. The magnetic resonance imaging findings indicated a retroperitoneal tumor \[[Fig. 1(a)](#F1){ref-type="fig"}\]. Treatment with fluid replacement, zoledronic acid, and elcatonin lowered the serum calcium level. However, shortly thereafter, the tumor became enlarged, and the serum calcium level increased again despite intensive therapy. Whole body computed tomography and bone scintigraphy revealed no signs of metastasis, suggesting that the retroperitoneal tumor secreted PTH. The tumor was surgically resected. Pathologically, most tumor cells were spindle-shaped and the interspersed giant cells had large atypical nuclei \[[Fig. 1(b)](#F1){ref-type="fig"}\]. The tumor was immunohistochemically positive for vimentin, CD34, smooth muscle actin, and cytokeratin (AE1/AE3) *α*S100 (partially). Therefore, we diagnosed an MFH. After tumor resection, the serum iPTH concentration decreased dramatically to 23 pg/mL and the serum calcium level normalized \[[Fig. 1(c)](#F1){ref-type="fig"}\].

![The MFH tumor and clinical course. (a) Enhanced coronal magnetic resonance image of the abdomen at hospitalization. An arrow indicates the retroperitoneal mass, 63 × 66 × 55 mm in size. (b) Hematoxylin and eosin staining of the retroperitoneal tumor (magnification, ×200). (c) Serum calcium and intact PTH levels in response to treatment with zoledronic acid, elcatonin, and tumor resection. (d) PTH expression in the MFH+P. The MFH+P tumor was cultured in DMEM for 2 hours, followed by measurement of whole PTH. A mock incubation medium served as a control. (e--h) Immunohistochemistry for PTH (magnification, ×200). (e) MFH+P tumor and (f) PA were stained with a mouse monoclonal anti-human PTH antibody. (g) MFH+P and (h) PA were stained with mouse IgG as negative controls. (i) qRT-PCR to assay the expression of PTH from the MFH+P and PA tumors and non--PTH-producing MCF-7 cells. The data were normalized by comparison with GAPDH expression.](js-01-691-f1){#F1}

The whole PTH concentration in the supernatant of the tumor cultured in DMEM was 4830 pg/mL \[reference range, 10 to 39; [Fig. 1(d)](#F1){ref-type="fig"}\], implying that the tumor cells produced PTH. After discharge, the serum iPTH and calcium levels have been normal for 6 years with no tumor recurrence.

B. PTH Expression in the Tumor {#s13}
------------------------------

We examined PTH expression by immunohistochemistry. The tumor was stained with an anti-PTH antibody \[[Fig. 1(e)](#F1){ref-type="fig"}\], similar to the PA \[[Fig. 1(f)](#F1){ref-type="fig"}\]. Normal mouse IgG gave no signal \[[Fig. 1(g)](#F1){ref-type="fig"} and [1(h)](#F1){ref-type="fig"}\]. We then measured the amount of PTH mRNA using qRT-PCR \[[Fig. 1(i)](#F1){ref-type="fig"}\]. We used the PA as a positive control, and non--PTH-expressing MCF-7 cells were used as a negative control. PTH mRNA expression was exceedingly high, comparable to that of the PA. PTHrP expression was not detected (data not shown).

C. Structural Analysis of the PTH Gene {#s14}
--------------------------------------

To examine whether structural alteration of the PTH gene was responsible for the elevation \[[@B48]\], we examined PCR-amplified genomic regions of the PTH gene. We found neither any mutations in the coding and promoter sequences of the PTH gene nor hypomethylation of CpG dinucleotides in the PTH promoter (Supplemental Fig. 1). Sanger sequencing gave us consistent results. We did not find cyclin D overexpression in the MFH+P sample compared with four other non--PTH-producing MFHs or PA \[[@B49][@B50]--[@B51]\] ([Fig. 2](#F2){ref-type="fig"}). Importantly, the 5′-flanking 5500-bp region of the PTH gene, which is necessary and sufficient to direct the parathyroid-specific expression of various transgenes in addition to the endogenous PTH gene \[[@B50], [@B52]\], contained no mutations.

![Cyclin D1 expression in the five MFHs (including the MFH+P), PA, and MCF-7 cells. (a) Comparison among the MFH+P and the four other MFHs (GSM149191, GSM14913, GSM149194, and GSM149200). Data were obtained from the registered microarray panel \[[@B45]\]. Green-to-red corresponds to elevated-to-reduced expression compared with that in the MFH+P. Two different probes were used. Numbers with a minus sign indicate an increase, and those without indicate a decrease in the mRNA level in MFH+P cells compared with each MFH (represented as an exponent of 2). (b) qRT-PCR of cyclin D1 mRNA from three cell types: MFH+P, PA, and MCF-7 breast cancer-cultured cells.](js-01-691-f2){#F2}

D. Global Analysis of Gene Expression {#s15}
-------------------------------------

We obtained the global expression profile of the MFH+P using microarray analyses ([Fig. 3](#F3){ref-type="fig"}). As a control, we selected four non--PTH-producing MFHs, whose results we have made publicly accessible \[[@B45]\]. Of the four MFHs, one (termed GSM149194) originated from the retroperitoneum, similar to the MFH+P. As expected, PTH was one of the most highly activated genes ([Fig. 3](#F3){ref-type="fig"}). Gene ontology analyses of the tumor (Supplemental Tables 2--5) revealed that molecules ensuring the spatiotemporal expression of genes only in the parathyroid environment \[[@B53][@B54][@B55]--[@B56]\] were not included in the MFH+P. The expression of the Gcm2 gene ([Fig. 3](#F3){ref-type="fig"}), a master regulator of parathyroid gland development \[[@B56]\], was low in the MFH+P.

![Transcriptional activation of the PTH gene through multiple mechanisms. A heatmap representing the expression levels of developmental genes for parathyroid genesis, transcriptional activators for PTH expression, proteins binding to PTH mRNA, and histone acetyltransferases in the MFH+P compared with those of the four other non--PTH-producing MFHs. Data were obtained from the registered microarray panel \[[@B45]\]. Green-to-red corresponds to elevated-to-reduced expression compared with that in MFH+P.](js-01-691-f3){#F3}

Furthermore, our subsequent qRT-PCR analysis using our MFH+P and the MFH GSM149194 revealed that the difference in the expression of PTH gene-related transcriptional and post-transcriptional factors was 2.5-fold at most between both (Supplemental Fig. 2) \[[@B48], [@B57][@B58][@B59]--[@B60]\].

Other candidates included redox factor 1 (apurinic/apyrimidinic endonuclease) and DNA-dependent protein kinase. We previously proposed that these two proteins were required for the extracellular calcium-dependent reduction of PTH mRNA \[[@B61][@B62]--[@B63]\]. We also wondered whether these proteins could function as negative regulators of the expression of certain genes in nonparathyroid cells \[[@B62]\]. Nonetheless, the expression levels of redox factor 1 and DNA-dependent protein kinase, and its regulatory subunits Ku70 and Ku86 were largely similar among the 5 MFHs and PA (Supplemental Fig. 3).

E. Whole Exome Sequencing {#s16}
-------------------------

Whole exome sequencing revealed a frameshift mutation near the middle of the protein-coding region of the *α*-thalassemia/mental retardation syndrome X-linked (ATRX) gene and non--silent exonic mutations in 25 other genes \[[@B64][@B65]--[@B66]\] ([Table 3](#T3){ref-type="table"}). DNA from the patient's WBCs was used as a reference. The details of the analyses, including WBCs in the coding sequence in both samples, are shown in Supplemental Fig. 4. Because this gene is located on the X chromosome and its C-terminal portion has a crucial functional role as a tumor suppressor or chromosome modifier, our exome sequence analyses ruled out the possibility of an exon-breaking translocation with known genes (data not shown). In addition, we found \>10 chromosomal copy number variations clustered at chromosome 11, where similar findings have been found in several PAs and hyperplasia ([Table 4](#T4){ref-type="table"}) \[[@B51], [@B67], [@B68]\].

###### 

**Whole Exome Sequencing of Paired MFH Tissues (MFH+P vs White Blood Cells)**

  Gene                                      Exonic Function        AA Change
  ----------------------------------------- ---------------------- --------------------------------------
  USP24                                     Frameshift insertion   uc001cyg.4:c.5124_5125insT:p.I1708fs
  PVRL4                                     Nonsynonymous SNV      uc010pjy.1:c.C311T:p.T104M
  IPO9                                      Nonsynonymous SNV      uc001gwz.3:c.C1738T:p.L580F
  DUSP10                                    Nonsynonymous SNV      uc001hmy.2:c.T463G:p.L155V
  LRP2                                      Nonsynonymous SNV      uc002ues.3:c.C10416A:p.N3472K
  TTN                                       Nonsynonymous SNV      uc021vtb.1:c.G67412A:p.S22471N
  PGAP1                                     Nonsynonymous SNV      uc010fsi.3:c.T97C:p.Y33H
  TBC1D19                                   Nonsynonymous SNV      uc011bxu.2:C1318T:p.L440F
  RBM47                                     Nonsynonymous SNV      uc003gvd.2:c.G122A:p.R41H
  RICTOR                                    Nonsynonymous SNV      uc003jlo.2:c.G2402T:p.G801V
  PCDHA8                                    Nonsynonymous SNV      uc003lhr.1:c.G372T:p.K124N
  UBR5                                      Nonsynonymous SNV      uc003ykr.2:c.G5227A:p.G1743S
  LIPF                                      Nonsynonymous SNV      uc001kfg.2:c.T412C:p.W138R
  MS4A6A                                    Nonsynonymous SNV      uc010rlb.2:c.T439G:p.C147G
  BATF2                                     Nonsynonymous SNV      uc021qlb.1:c.C143T:p.A48V
  DYNC2H1                                   Stopgain SNV           uc001pho.2:c.C12049T:p.Q4017X
  CD163L1                                   Nonsynonymous SNV      uc001qsy.3:c.G4297T:p.G1433C
  EEA1                                      Nonsynonymous SNV      uc001tck.3:c.G3228T:p.L1076F
  ESRP2                                     Nonsynonymous SNV      uc002evq.1:c.G199C:p.V67L
  MED1                                      Nonsynonymous SNV      uc010wee.2:c.C199T:p.P67S
  FAM59A                                    Nonsynonymous SNV      uc002kxk.2:c.C2168T:p.A723V
  RTTN                                      Nonsynonymous SNV      uc002lkp.2:c.G554A:p.R185K
  ZNF335                                    Nonsynonymous SNV      uc010zxk.2:c.G1278A:p.M426I
  ATRX[*^a^*](#t3n1){ref-type="table-fn"}   Frameshift insertion   uc004ecq.4:c.3232_3233insT:p.S1078fs
  GRIA3                                     Nonsynonymous SNV      uc004etq.4:c.C303G:p.I101M
  GRIA3                                     Nonsynonymous SNV      uc004etq.4:c.C335T:p.T112I

Among 137 somatic mutations (123 SNVs, 14 indels), 39 exonic mutations, including 26 non-silent mutations (shown) were observed.

ATRX with a frameshift mutation.

###### 

**Summary of Allelic Copy Number Variation (Both Gain and Loss)**

  Chromosome   Start         End           Copy Number   Gain/Loss   Number of Heterozygous SNPs
  ------------ ------------- ------------- ------------- ----------- -----------------------------
  Chr2         41,686        49,215,977    1.0           Loss        1,094
  Chr2         160,087,535   163,080,793   3.0           Gain        69
  Chr2         166,894,230   169,020,166   3.0           Gain        36
  Chr2         241,737,017   241,826,517   3.0           Gain        9
  Chr2         241,826,754   242,265,313   4.0           Gain        77
  Chr2         242,274,489   242,443,377   3.0           Gain        10
  Chr3         12,616,533    13,679,335    3.0           Gain        38
  Chr3         13,679,688    15,492,807    4.0           Gain        84
  Chr3         15,507,761    16,280,076    3.0           Gain        31
  Chr3         52,771,468    52,814,256    3.0           Gain        8
  Chr3         52,815,905    54,615,971    4.0           Gain        52
  Chr3         54,667,912    55,108,167    3.0           Gain        8
  Chr4         40,337,908    44,704,938    3.0           Gain        69
  Chr4         81,122,806    85,730,914    3.0           Gain        53
  Chr4         142,155,214   143,236,158   3.0           Gain        9
  Chr4         143,268,528   150,631,973   4.0           Gain        82
  Chr4         150,632,186   152,049,296   3.0           Gain        13
  Chr6         150,322,211   152,630,946   3.0           Gain        68
  Chr7         154,680,910   157,232,668   3.0           Gain        107
  Chr7         158,455,089   159,026,164   3.0           Gain        0
  Chr9         107,586,753   111,635,101   3.0           Gain        65
  Chr9         132,175,588   138,660,548   3.0           Gain        279
  Chr9         140,507,688   141,071,552   3.0           Gain        0
  Chr11        193,051       1,273,002     1.0           Loss        246
  Chr11        1,272,245     5,565,906     3.0           Gain        244
  Chr11        2,357,128     5,617,987     1.0           Loss        172
  Chr11        5,573,024     6,737,979     4.0           Gain        62
  Chr11        6,737,706     12,264,140    1.0           Loss        183
  Chr11        6,738,291     17,491,571    3.0           Gain        252
  Chr11        17,496,516    17,612,888    4.0           Gain        24
  Chr11        17,612,972    26,700,099    3.0           Gain        172
  Chr11        19,890,441    20,411,424    1.0           Loss        35
  Chr11        26,718,692    33,075,917    4.0           Gain        64
  Chr11        33,075,933    46,896,908    3.0           Gain        210
  Chr11        33,778,729    41,830,789    1.0           Loss        94
  Chr11        100,921,665   101,454,192   3.0           Gain        8
  Chr11        101,762,478   102,736,642   4.0           Gain        59
  Chr11        102,742,515   103,006,557   3.0           Gain        9
  Chr12        57,030,026    57,109,931    3.0           Gain        8
  Chr12        57,112,637    70,735,733    4.0           Gain        178
  Chr12        70,740,194    70,930,061    3.0           Gain        7
  Chr12        71,003,360    79,611,536    3.0           Gain        64
  Chr13        32,915,413    36,822,849    3.0           Gain        70
  Chr14        31,425,457    31,922,408    3.0           Gain        10
  Chr14        32,047,217    36,400,983    4.0           Gain        45
  Chr14        36,603,728    38,367,694    3.0           Gain        36
  Chr14        38,368,184    45,432,870    4.0           Gain        46
  Chr14        45,433,155    47,770,498    3.0           Gain        11
  Chr15        66,641,956    72,143,855    3.0           Gain        125
  Chr16        57,149,645    58,457,327    3.0           Gain        63
  Chr18        12,976        3,075,778     3.0           Gain        94
  Chr18        10,759,961    14,866,547    3.0           Gain        88
  Chr18        32,487,955    50,912,352    3.0           Gain        136
  Chr18        56,203,120    60,029,217    3.0           Gain        56
  Chr19        308,662       6,677,989     3.0           Gain        484
  Chr19        9,449,888     16,000,609    3.0           Gain        402
  Chr19        16,006,101    16,976,289    4.0           Gain        60
  Chr19        16,977,060    32,501,502    3.0           Gain        447
  Chr19        41,198,482    41,415,818    3.0           Gain        46
  Chr20        61,870,727    62,737,877    3.0           Gain        0
  Chr21        9,825,948     32,965,213    3.0           Gain        265
  Chr21        35,230,780    38,009,239    3.0           Gain        60
  Chr21        44,783,270    44,838,097    3.0           Gain        17
  Chr21        44,841,036    46,020,721    4.0           Gain        97
  Chr21        46,021,088    46,419,158    3.0           Gain        37
  Chr21        47,546,244    47,614,660    3.0           Gain        13
  Chr21        47,616,071    48,078,611    4.0           Gain        0

CNVs in chromosome 11 constituted \>20% of all CNVs in the MFH+P sample.

Abbreviations: Chr, chromosome; CNV, copy number variation; SNP, single nucleotide polymorphism.

F. CaSR and CYP24A1 Levels in the MFH+P Tumor {#s17}
---------------------------------------------

We next focused on molecules known to be specifically engaged in the regulation of PTH expression. We examined the expression of CaSR in five MFHs, including the MFH+P. CaSR mRNA was undetectable in all five MFH tumors, with little variance \[[Fig. 4(a)](#F4){ref-type="fig"}\]. We then focused on the MFH+P by measuring CaSR mRNA levels using qRT-PCR. Compared with the PA, in which CaSR expression was robust, CaSR expression was almost undetectable in our MFH+P \[[Fig. 4(b)](#F4){ref-type="fig"}\]. Dissociation curves after RT-PCR amplification \[[Fig. 4(c)](#F4){ref-type="fig"}\] of MFH+P cDNA showed apparently bizarre shapes compared with the expected curves obtained from the PA, suggesting these were not primer dimers but indicating essentially no CaSR mRNA was expressed in the MFH+P. This was also the case for many other cultured cancer cells.

![CaSR mRNA by microarray and real-time qRT-PCR. (a) Comparison among the MFH+P and the four other MFHs. Data were obtained from the registered microarray panel \[[@B45]\]. (Left) The corresponding heatmap is indicated. Green-to-red corresponds to elevated-to-reduced expression compared with that in the MFH+P. Two (CaSR) and four (VDR) different probe sets were used. For CYP24A1 and HIC1 mRNAs, only one probe was used, respectively. Numbers with a minus sign indicate an increase, and those without indicate a decrease in the mRNA level in MFH+P cells compared with each MFH (represented as an exponent of 2). (b) qRT-PCR of CaSR/*β*-actin mRNA. MFH+P (black) and two different preparations of PAs (white). The MFH+P number (approximately 1, which was tagged with an asterisk) was probably of no significance (see Fig. c). (c) Dissociation curves of the amplified cDNAs other than those derived from PA, MT2, and SKBR cells suggested that these nonparathyroid cells do not express substantial levels of CaSR mRNA. \*\*MFH+P, HepG2 (hepatoma), M059J (glioma), HaCaT (keratinocyte), H295R (adrenocortical), and RV22 (prostate cancer) cells. (d) qRT-PCR of VDR/*β*-actin in MFH-P (GSM149194), MFH+P (black), two PAs, and other cultured cells. \*LNCaP cells represent LNCaP cells treated with 1,25-dihydroxyvitamin D3 (10^−8^ M) for 24 hours. (e) qRT-PCR of CYP24A1/*β*-actin in MFH-P (GSM149194), MFH+P (black), two PAs (white), and other cultured cells. Two separate preparations of PAs yielded no PCR products. To validate the qRT-PCR data with (c) CaSR, (d) VDR, and (e) CYP24A1, we used two different sets of primers covering separate positions of each cDNA. In each, the data were similar and the results from one set are shown.](js-01-691-f4){#F4}

Another brake system for PTH expression is the 1,25-dihydroxyvitamin D3--VDR axis. Thus, we re-examined the expression of VDR in the MFH+P. The amount of VDR in the MFH+P was 1/20th of that in the PA \[[@B69]\]. The VDR cDNA levels in the other four MFH samples or cultured cancer cells varied \[[Fig. 4(a)](#F4){ref-type="fig"} and [4(d)](#F4){ref-type="fig"}\]. Furthermore, qRT-PCR analysis of the MFH+P \[[Fig. 4(e)](#F4){ref-type="fig"}\] revealed the remarkable overexpression of CYP24A1, which is a target gene of the VDR and inactivates 1,25-dihydroxyvitamin D3 via 24-hydroxylation. Our microarray panel showed that among the five MFHs examined, CYP24A1 was expressed at the greatest level in our MFH+P compared with the four other non--PTH-producing MFHs \[[Fig. 4(e)](#F4){ref-type="fig"}\]. Our qRT-PCR assay confirmed that the MFH GSM149194 expressed CYP24A1 mRNA at less than 1/100th of the level observed in MFH+P cells. The two PAs did not express CYP24A1 \[[Fig. 4(e)](#F4){ref-type="fig"}\]. These results suggest that CYP24A1 itself might be deeply involved in ectopic PTH production in MFH+P cells \[[@B7][@B8][@B9][@B10][@B11][@B12][@B13]--[@B14]\]. In contrast, CYP24A1 mRNA levels varied in various cultured cancer cells \[[Fig. 4(e)](#F4){ref-type="fig"}\].

The CYP24A1 gene is potently suppressed by the HIC1 tumor suppressor \[[@B15][@B16]--[@B17]\]. Microarray profiling revealed that the four non--PTH-producing MFHs expressed sixfold or greater levels of HIC1 mRNA than the MFH+P \[[Fig. 4(a)](#F4){ref-type="fig"}\], and a subsequent qRT-PCR assay revealed that the MFH+P expressed \<30-fold HIC1 mRNA compared with MFH GSM149194 (data not shown). Although unconfirmed, these data suggest that HIC1 underexpression might trigger CYP24A1 overexpression in MFH+P cells \[[@B15][@B16]--[@B17]\].

G. Immunofluorescence Microscopy {#s18}
--------------------------------

Next, the expression of CYP24A1, VDR, and CaSR was compared between PA and MFH+P cells by immunofluorescence microscopy \[[Fig. 5(a--c)](#F5){ref-type="fig"}\]. We found that all the data obtained at the protein level were concordant with the corresponding qRT-PCR data at the mRNA level. CYP24A1 protein was highly expressed in MFH+P cells but not in PA cells. In contrast, CaSR protein was exclusively present on the surface of PA cells but not MFH+P cells. Finally, the level of VDR was quite different between the two, with greater amounts of VDR observed in the PA sample. This finding might also explain the notable lack of the vitamin D--VDR signaling system in the MFH+P. These data, along with the mRNA content of each cell type, are summarized in [Fig. 5(d)](#F5){ref-type="fig"}.

![Expression of (a) CaSR, (b) VDR, and (c) CYP24A1 examined by immunostaining. (d) A summary is also provided. (d) The data regarding the normal parathyroid were obtained from Sudhaker Rao *et al.* \[[@B69]\] and Corbett *et al.* \[[@B87]\], which compared the amounts of the indicated items between parathyroid adenoma and normal parathyroid. In each figure, the MFH+P cells (top three panels) and PA cells (bottom three panels) were fixed with 4% paraformaldehyde and stained with each antibody. Red staining indicates data obtained using each antibody, and blue staining shows 496-diamidine-29-phenylindole dihydrochloride (DAPI) (cell nuclei). Scale bars = 100 μm.](js-01-691-f5){#F5}

H. lncRNA Recognized Only in the PA and PTH-Producing MFH+P Samples {#s19}
-------------------------------------------------------------------

Finally, we explored whether lncRNAs are another candidate driver of the commonality in PTH overexpression. The DNA sequences in the 3′-flanking region of the human PTH gene are responsible for calcium- and phosphate-mediated PTH gene regulation, although the exact location or specific players interacting with the DNA/RNA sequences remain partially unknown \[[@B70], [@B71]\]. After a random serial qRT-PCR survey using primers scattered 20 to 50 kbp downstream of the human PTH gene to identify tissue-specific transcripts, we detected several distinct species of lncRNA of 800 to 3800 bases in length (data not shown). The expression of at least one of these lncRNAs of 2533 bases covering no PTH exonic sequence ([Fig. 6](#F6){ref-type="fig"}, region A) was exclusively found in the PA and MFH+P samples but not in the other cultured cancer cell lines examined. GAPDH mRNA expression was analyzed among the samples using qRT-PCR, and it varied less than threefold in all samples (data not shown). Our observation that other sets of RT-PCR primers adjacent to this 2533-base region did not capture any nucleic acids in these cells confirmed that our samples, except for the positive control, did not contain detectable amounts of residual DNA. Furthermore, the nucleotide sequence of this lncRNA did not match any other in open or public databases of lncRNA, such as LNCipedia (available at: <http://www.lncipedia.org/>) or NONCODE (available at: <http://www.noncode.org/>), suggesting this is an lncRNA expressed within a very narrow range of cell types.

![lncRNA. After random scanning with real-time qRT-PCR using various primers to search for tissue-specific transcripts, the 2- to 5-kbp candidate region spanning each primer set that yielded positive results in this screening was amplified for lncRNA detection, and the samples were loaded onto a 0.9% agarose gel. "P" denotes a positive control obtained from a crude mRNA fraction of MCF-7 cells in which certain amounts of residual genomic DNA were left after no further DNase treatment. GAPDH mRNA expression in the samples was analyzed by qRT-PCR, and the differences among them were all less than threefold (data not shown). The position of the start point of exon 1 was arbitrarily marked as 5001. Transcripts from the region denoted as "A" were detected. The six other 3′-flanking positions shown were not amplified even in the PA and MFH+P samples. In contrast, the positive control containing genomic DNA was clearly amplified in each case (data not shown). These results also support the validity of the lncRNA in our RNA samples from the PA and MFH+P tumors. "MFH+P-2" denotes the cDNA from the same MFH+P obtained on a different occasion.](js-01-691-f6){#F6}

3. Discussion {#s20}
=============

Our study included only one ectopic PTH-producing tumor. Notwithstanding, to the best of our knowledge, our report of this extremely rare tumor uses microarray data mining and whole exome sequencing. We believe that our findings could be a scaffold for understanding the pathogenesis of ectopic PTH-producing tumors.

We found that the levels of various transcription factors determining parathyroid differentiation during development, including transcription factors involved in PTH gene expression \[[@B48], [@B53][@B54][@B55][@B56][@B57][@B58][@B59][@B60][@B61][@B62]--[@B63]\], were not significantly dysregulated in the MFH+P ([Figs. 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}).

Whole exome sequencing revealed a frameshift mutation in the ATRX gene \[[@B64]\] ([Table 3](#T3){ref-type="table"}). Defects in ATRX have been shown to be a driver for pancreatic neuroendocrine tumors; however, these mutations have never been linked to PTH expression \[[@B64][@B65]--[@B66]\]. In addition, the significance of the copy number variation observed in chromosome 11 in the MFH+P ([Table 4](#T4){ref-type="table"}) remains unknown.

We explored the behavior of CaSR in our samples. CaSR expression was almost undetectable in the MFH+P \[[Figs. 4(a--c)](#F4){ref-type="fig"} and [5(c)](#F5){ref-type="fig"}\], suggesting a close relationship between the absence of CaSR and PTH expression. Lethal hypercalcemia in mice and humans can be induced by systemic inactivity of the CaSR gene and PTH overexpression in the parathyroid \[[@B39][@B40]--[@B41]\]. Thus, if any first hit triggers PTH production in nonparathyroid cells, a chance might exist that its expression would be reinforced via disruption of the CaSR signal transduction system \[[@B72][@B73][@B74]--[@B75]\]. The absence of CaSR in the adult parathyroid has been reported to be a possible trigger for parathyroid tumor formation \[[@B76]\].

Our microarray profiling revealed robust CYP24A1 mRNA expression in the MFH+P \[[Fig. 4(e)](#F4){ref-type="fig"}\] compared with the other MFH GSM149194. Ablation of the vitamin D--VDR signaling system by whole-body VDR disruption increases PTH expression in the parathyroid gland but not in nonparathyroid cells elsewhere \[[@B56], [@B73], [@B77][@B78][@B79][@B80]--[@B81]\]. Our qRT-PCR and immunofluorescence analyses showed that CYP24A1 was barely present in the PA \[[Figs. 4(e)](#F4){ref-type="fig"} and [5(a)](#F5){ref-type="fig"}\]. Therefore, once PTH expression occurs by unknown mechanisms, intratumor hypovitaminosis D might be related to the tumorigenesis of MFH+P. CYP24A1 overexpression as an oncogene or an intracellular repressor of active vitamin D signaling might play a provocative role in the development of several cancers \[[@B28][@B29][@B30][@B31][@B32][@B33][@B34]--[@B35]\]. HIC1 is a tumor suppressor gene \[[@B36]\]. We found the MFH+P-specific underexpression of HIC1 mRNA \[[Fig. 4(a)](#F4){ref-type="fig"}\]. Because HIC1 also represses CYP24A1 expression \[[@B37], [@B38], [@B82]\], these data suggest that HIC1 underexpression might trigger CYP24A1 overexpression in MFH+P.

These three combinations (PTH overproduction, lack of CaSR expression, overexpression of CYP24A1, and the paucity of the two braking systems) are summarized in [Fig. 5(d)](#F5){ref-type="fig"}. However, the combination of a large amount of CYP24A1 protein in the absence of CaSR is not a rare event \[[Fig. 4(a--c)](#F4){ref-type="fig"} and [4(e)](#F4){ref-type="fig"}\], implying that both molecules cannot be *bona fide* MFH+P drivers, However, our discovery that an lncRNA in a nonexonic region of the human PTH gene is expressed exclusively in the PA and MFH+P ([Fig. 6](#F6){ref-type="fig"}) raises the possibility that this lncRNA might be one of the long sought-after factors determining PTH expression, although this hypothesis is totally speculative at present. Recent work has identified lncRNAs as tumorigenesis promoters, chromatin modifiers, and, especially, tissue-specific expression regulators \[[@B41][@B42]--[@B43], [@B83]\]. Because transfectable PTH-producing cells are unavailable, the exogenous overexpression of this RNA in either direction in various non--PTH-producing cultured cells would clarify its role in PTH production.

PTHrP stimulates CYP27B1 *in vitro* via PT1R, identical to the PTH receptor. However, serum 1,25(OH)~2~ vitamin D3 levels in humoral hypercalcemia of malignancy due to PTHrP overexpression are often low, just as was seen in our MFH+P ([Table 2](#T2){ref-type="table"}). Although speculative, some inhibitory molecules for CYP27B1 production postulated in such cases \[[@B84][@B85]--[@B86]\] might also be involved in our MFH+P, which could be an accelerator of CYP24D1 in turn.

Overall, the similarities and dissimilarities of the PTH-regulator molecules among the PA, PTH-producing MFH, and non--PTH-producing MFH samples would provide us with a dynamic profile of potential pathogenic factors.

Abbreviations: ATRX*α*-thalassemia/mental retardation syndrome X-linkedCaSRcalcium-sensing receptorcDNAcomplementary DNACYP24A1cytochrome P450 family 24 subfamily A member 1DMEMDulbecco's modified Eagle mediumGAPDHglyceraldehyde 3-phosphate dehydrogenaseHIC1hypermethylated in cancer 1iPTHintact parathyroid hormonelncRNAlong noncoding RNAMFHmalignant fibrous histiocytomaMFH+Pparathyroid hormone-producing malignant fibrous histiocytomaPAparathyroid adenomaPBSphosphate-buffered salinePCRpolymerase chain reactionPTHparathyroid hormonePTHrPparathyroid hormone-related proteinqRT-PCRquantitative real-time reverse transcription polymerase chain reactionSNVsingle nucleotide variationVDRvitamin D receptorWBCwhite blood cell.
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